{"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"FG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"FG001","title":"Sunitinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"95"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"368"},{"groupId":"FG001","numSubjects":"325"}],"type":"Ongoing in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"432"},{"groupId":"FG001","numSubjects":"429"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"429"},{"groupId":"FG001","numSubjects":"425"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"432"},{"groupId":"FG001","numSubjects":"429"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"These interim results are based on a database cutoff date of 24-Aug-2018, at which time 693 participants were ongoing in the study."}